- Home
- VRAX vs UMAC Comparison
VRAX vs UMAC Comparison
Compare VRAX & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- UMAC
- Stock Information
- Founded
- VRAX 2013
- UMAC 2019
- Country
- VRAX United Kingdom
- UMAC United States
- Employees
- VRAX N/A
- UMAC N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- UMAC
- Sector
- VRAX Health Care
- UMAC
- Exchange
- VRAX Nasdaq
- UMAC Nasdaq
- Market Cap
- VRAX 17.2M
- UMAC 20.4M
- IPO Year
- VRAX 2022
- UMAC 2024
- Fundamental
- Price
- VRAX $1.97
- UMAC $3.22
- Analyst Decision
- VRAX
- UMAC Strong Buy
- Analyst Count
- VRAX 0
- UMAC 1
- Target Price
- VRAX N/A
- UMAC $4.00
- AVG Volume (30 Days)
- VRAX 4.9M
- UMAC 126.4K
- Earning Date
- VRAX 11-26-2024
- UMAC 11-14-2024
- Dividend Yield
- VRAX N/A
- UMAC N/A
- EPS Growth
- VRAX N/A
- UMAC N/A
- EPS
- VRAX N/A
- UMAC N/A
- Revenue
- VRAX $156,419.00
- UMAC $2,030,039.00
- Revenue This Year
- VRAX $5,169.18
- UMAC N/A
- Revenue Next Year
- VRAX $66.97
- UMAC $66.18
- P/E Ratio
- VRAX N/A
- UMAC N/A
- Revenue Growth
- VRAX 1727.11
- UMAC N/A
- 52 Week Low
- VRAX $0.60
- UMAC $0.98
- 52 Week High
- VRAX $9.00
- UMAC $5.54
- Technical
- Relative Strength Index (RSI)
- VRAX 46.98
- UMAC 75.40
- Support Level
- VRAX $1.92
- UMAC $2.45
- Resistance Level
- VRAX $2.50
- UMAC $3.53
- Average True Range (ATR)
- VRAX 0.22
- UMAC 0.44
- MACD
- VRAX 0.01
- UMAC 0.15
- Stochastic Oscillator
- VRAX 26.97
- UMAC 85.24
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is a development stage technology company.